Review
doi: 10.1016/j.ceb.2008.12.011.
Epub 2009 Feb 7.
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents
Affiliations
- PMID: 19201591
- DOI: 10.1016/j.ceb.2008.12.011
Item in Clipboard
Review
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents
Curr Opin Cell Biol.
2009 Apr.
Abstract
Epidemiological and experimental studies support an important role of the phosphoinosite 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway in the biology of human cancers. Over the past few years a number of components of this signaling cascade have been the subject of intense drug discovery activities. This article summarizes progress made in the identification of kinase inhibitors of PI3K and mTOR, with an emphasis placed on drugs currently undergoing clinical trials. Potential combination strategies, safety concerns, and resistance mechanisms for this new generation of anticancer agents are also discussed.
Similar articles
-
Targeting mTOR for cancer treatment.Curr Opin Investig Drugs. 2006 Jun;7(6):501-12. Curr Opin Investig Drugs. 2006. PMID: 16784020 Review.
-
[mTOR signal pathway and its inhibitors in antitumor therapy: a review].Ai Zheng. 2007 Dec;26(12):1397-403. Ai Zheng. 2007. PMID: 18076811 Review. Chinese.
-
Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.J BUON. 2006 Jul-Sep;11(3):267-76. J BUON. 2006. PMID: 17309148 Review.
-
The biology behind mTOR inhibition in sarcoma.Oncologist. 2007 Aug;12(8):1007-18. doi: 10.1634/theoncologist.12-8-1007. Oncologist. 2007. PMID: 17766661 Review.
-
Targeting mTOR signaling in lung cancer.Crit Rev Oncol Hematol. 2007 Aug;63(2):172-82. doi: 10.1016/j.critrevonc.2007.04.002. Epub 2007 May 30. Crit Rev Oncol Hematol. 2007. PMID: 17540577 Review.
Cited by
-
Rapamycin and rapalogs for tuberous sclerosis complex.Cochrane Database Syst Rev. 2023 Jul 11;7(7):CD011272. doi: 10.1002/14651858.CD011272.pub3. Cochrane Database Syst Rev. 2023. PMID: 37432030 Free PMC article. Review.
-
NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2).Cells. 2022 Nov 22;11(23):3719. doi: 10.3390/cells11233719. Cells. 2022. PMID: 36496978 Free PMC article.
-
Nanotechnology-Based Targeting of mTOR Signaling in Cancer.Int J Nanomedicine. 2020 Aug 6;15:5767-5781. doi: 10.2147/IJN.S254574. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32821100 Free PMC article. Review.
-
Mechanisms of Action of Autophagy Modulators Dissected by Quantitative Systems Pharmacology Analysis.Int J Mol Sci. 2020 Apr 19;21(8):2855. doi: 10.3390/ijms21082855. Int J Mol Sci. 2020. PMID: 32325894 Free PMC article.
-
Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine.Front Oncol. 2020 Feb 19;10:174. doi: 10.3389/fonc.2020.00174. eCollection 2020. Front Oncol. 2020. PMID: 32140451 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
